PMID- 32874955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2220-3206 (Print)
IS  - 2220-3206 (Electronic)
IS  - 2220-3206 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 19
TI  - Serum levels of chemokines in adolescents with major depression treated with 
      fluoxetine.
PG  - 175-186
LID - 10.5498/wjp.v10.i8.175 [doi]
AB  - BACKGROUND: Major depressive disorder (MDD) is a global health issue that affects 
      350 million people of all ages. Although between 2% and 5.6% of affected 
      individuals are adolescents, research on young patients is limited. The 
      inflammatory response contributes to the onset of depression, and in adult MDD 
      patients, symptom severity has been linked to chemokine levels. AIM: To determine 
      the differences in circulatory levels of chemokines in healthy volunteers (HVs) 
      and adolescents with MDD, and assess the changes induced by fluoxetine consume. 
      METHODS: The 22 adolescents with MDD were monitored during the first 8 wk of 
      clinical follow-up and clinical psychiatric evaluation was done using the 
      Hamilton depresion rating scale (HDRS). The serum levels of monocyte 
      chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, 
      MIP-1beta, interleukin (IL)-8, interferon gamma-induced protein (IP)-10, and eotaxin 
      were measured in patients and HVs. RESULTS: In all cases, significant differences 
      were detected in circulating chemokine levels between patients before treatment 
      and HVs (P < 0.0001). All chemokines decreased at 4 wk, but only MCP-1 and IL-8 
      significantly differed (P < 0.05) between 0 wk and 4 wk. In the patients, all 
      chemokines rose to their initial concentrations by 8 wk vs 0 wk, but only IP-10 
      did so significantly (P < 0.05). All patients experienced a significant decrease 
      in HDRS scores at 4 wk (P < 0.0001) and 8 wk (P < 0.0001) compared with 0 wk. 
      CONCLUSION: Despite the consumption of fluoxetine, patients had significantly 
      higher chemokine levels, even after considering the improvement in HDRS score. 
      The high levels of eotaxin, IP-10, and IL-8 partially explain certain aspects 
      that are affected in MDD such as cognition, memory, and learning.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - de la Pena, Francisco Rafael
AU  - de la Pena FR
AD  - Adolescent Clinic, Clinical Services, National Institute of Psychiatry, "Ramon de 
      la Fuente", Mexico City 14370, Mexico.
FAU - Cruz-Fuentes, Carlos
AU  - Cruz-Fuentes C
AD  - Department of Psychiatric Genetics, Clinical Research Branch, National Institute 
      of Psychiatry, "Ramon de la Fuente", Mexico City 14370, Mexico.
FAU - Palacios, Lino
AU  - Palacios L
AD  - Adolescent Clinic, Clinical Services, National Institute of Psychiatry, "Ramon de 
      la Fuente", Mexico City 14370, Mexico.
FAU - Giron-Perez, Manuel Ivan
AU  - Giron-Perez MI
AD  - Universidad Autonoma de Nayarit, Laboratorio de Inmunotoxicologia, Boulevard 
      Tepic-Xalisco s/n, Cd de la Cultura Amado Nervo, Tepic 63000, Mexico.
FAU - Medina-Rivero, Emilio
AU  - Medina-Rivero E
AD  - Unidad de Desarrollo e Investigacion en Bioprocesos, Escuela Nacional de Ciencias 
      Biologicas, Instituto Politecnico Nacional, Unidad Profesional Lazaro Cardenas, 
      Mexico City 11340, Mexico.
FAU - Ponce-Regalado, Maria Dolores
AU  - Ponce-Regalado MD
AD  - Departamento de Ciencias de Salud, Centro Universitario de los Altos, Universidad 
      de Guadalajara Av Rafael Casillas Aceves No.1200, Tepatitlan de Morelos, Jalisco, 
      47610, Mexico.
FAU - Alvarez-Herrera, Samantha
AU  - Alvarez-Herrera S
AD  - Laboratory of Psychoimmunology, National Institute of Psychiatry, "Ramon de la 
      Fuente", Mexico City 14370, Mexico.
FAU - Perez-Sanchez, Gilberto
AU  - Perez-Sanchez G
AD  - Laboratory of Psychoimmunology, National Institute of Psychiatry, "Ramon de la 
      Fuente", Mexico City 14370, Mexico.
FAU - Becerril-Villanueva, Enrique
AU  - Becerril-Villanueva E
AD  - Laboratory of Psychoimmunology, National Institute of Psychiatry, "Ramon de la 
      Fuente", Mexico City 14370, Mexico.
FAU - Maldonado-Garcia, Jose Luis
AU  - Maldonado-Garcia JL
AD  - Laboratory of Psychoimmunology, National Institute of Psychiatry, "Ramon de la 
      Fuente", Mexico City 14370, Mexico.
FAU - Jimenez-Martinez, Maria C
AU  - Jimenez-Martinez MC
AD  - Department of Immunology and Research Unit, Institute of Ophthalmology "Conde de 
      Valenciana Foundation", Mexico City 06800, Mexico.
FAU - Pavon, Lenin
AU  - Pavon L
AD  - Laboratory of Psychoimmunology, National Institute of Psychiatry, "Ramon de la 
      Fuente", Mexico City 14370, Mexico. lkuriaki@imp.edu.mx.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - World J Psychiatry
JT  - World journal of psychiatry
JID - 101610480
PMC - PMC7439300
OTO - NOTNLM
OT  - Adolescents
OT  - Chemokine
OT  - Fluoxetine
OT  - Interferon gamma-induced protein-10
OT  - Major depression
COIS- Conflict-of-interest statement: The authors report no conflicts of interest in 
      relation to the topic of this study.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
PMCR- 2020/08/19
CRDT- 2020/09/03 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/05/31 00:00 [revised]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
PHST- 2020/08/19 00:00 [pmc-release]
AID - 10.5498/wjp.v10.i8.175 [doi]
PST - epublish
SO  - World J Psychiatry. 2020 Aug 19;10(8):175-186. doi: 10.5498/wjp.v10.i8.175. 
      eCollection 2020 Aug 19.